高级检索

3种血清指标水平与晚期肺腺癌化疗患者预后的相关性分析

承柯伟, 方晓明, 吴玉英

承柯伟, 方晓明, 吴玉英. 3种血清指标水平与晚期肺腺癌化疗患者预后的相关性分析[J]. 实用临床医药杂志, 2020, 24(24): 10-12,16. DOI: 10.7619/jcmp.202024003
引用本文: 承柯伟, 方晓明, 吴玉英. 3种血清指标水平与晚期肺腺癌化疗患者预后的相关性分析[J]. 实用临床医药杂志, 2020, 24(24): 10-12,16. DOI: 10.7619/jcmp.202024003
shu
CHENG Kewei, FANG Xiaoming, WU Yuying. Analysis in correlations between prognosis and three serum indexes in patients with advanced lung adenocarcinoma with chemotherapy[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 10-12,16. DOI: 10.7619/jcmp.202024003
Citation: CHENG Kewei, FANG Xiaoming, WU Yuying. Analysis in correlations between prognosis and three serum indexes in patients with advanced lung adenocarcinoma with chemotherapy[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 10-12,16. DOI: 10.7619/jcmp.202024003
shu

3种血清指标水平与晚期肺腺癌化疗患者预后的相关性分析

  • 南京医科大学附属常州第二人民医院 呼吸与危重症医学科, 江苏 常州, 210029

详细信息

  • 中图分类号: R734.2;R730.43

Analysis in correlations between prognosis and three serum indexes in patients with advanced lung adenocarcinoma with chemotherapy

  • Department of Respiratory and Critical Care Medicine, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu, 210029

摘要

    摘要
  • 摘要: 目的 分析血清癌胚抗原(CEA)、乳酸脱氢酶(LHD)、甲状腺转录因子-1(TTF-1)水平与晚期肺腺癌化疗患者预后的相关性。 方法 选取晚期肺腺癌化疗患者62例作为研究对象,检测患者的血清CEA、LHD、TTF-1水平,随访2年内患者存活与病死情况,分析血清CEA、LHD、TTF-1水平与晚期肺腺癌化疗患者预后的关系。 结果 病死组血清CEA、LHD、TTF-1水平均高于存活组,差异有统计学意义(P<0.05); Logistic回归分析结果显示,血清CEA、LHD、TTF-1高表达是导致晚期肺腺癌化疗患者病死的危险因素(OR>1, P<0.01)。血清CEA、LHD、TTF-1水平预测晚期肺腺癌化疗患者预后的曲线下面积(AUC)均>0.7, 表明3个指标均具有预测价值。 结论 血清CEA、LHD、TTF-1可能参与晚期肺腺癌的发生与发展,与化疗患者预后密切相关,临床可通过检测血清CEA、LHD、TTF-1水平预估晚期肺腺癌化疗患者的预后情况。
    Abstract: Objective To analyze correlations between prognosis and serum carcinoembryonic antigen(CEA), lactate dehydrogenase(LHD), thyroid transcription factor-1(TTF-1)levels in patients with advanced lung adenocarcinoma undergoing chemotherapy. Methods A total of 62 patients with advanced lung adenocarcinoma undergoing chemotherapy were selected as research objects, their serum CEA, LHD, TTF-1 levels were detected, the relationships between serum CEA, LHD, TTF-1 levels and prognosis in patients with advanced lung adenocarcinoma undergoing chemotherapy were analyzed, and the conditions of survival and death of patients within 2 years of follow-up were explored. Results The serum CEA, LHD, and TTF-1 levels of the death group were higher than those of the survival group, and the differences were statistically significant(P<0.05). Logistic regression analysis showed that higher levels of serum CEA, LHD, and TTF-1 might be risk factors leading to death in patients with advanced lung adenocarcinoma undergoing chemotherapy(OR>1, P<0.01). The results showed that area under the curve(AUC)of the prognosis predicted by the levels of serum CEA, LHD, TTF-1 in advanced lung adenocarcinoma patients was above 0.7, which indicated that all the three indicators were of great value in predicting the disease. Conclusion Serum CEA, LHD, and TTF-1 may be involved in the occurrence and development of advanced lung adenocarcinoma, and are closely related to the prognosis of chemotherapy patients. Clinically, the prognosis of patients with advanced lung adenocarcinoma undergoing chemotherapy can be assessed by detecting serum CEA, LHD, and TTF-1 levels.
    • HTML全文
    • 参考文献(15)
  • 黄芳, 姜达, 李颖, 等. 晚期肺腺癌化疗方案的优化[J]. 肿瘤防治研究, 2015, 42(7): 687-692.
    刘月平, 刘俊英, 陈砚凝, 等. 不同组织学分型肺腺癌患者的临床特征及预后影响因素研究[J]. 中国全科医学, 2016, 19(11): 1272-1275.
    王黎明, 刘洋, 许顺. Ⅲ期非小细胞肺癌手术治疗患者预后因素分析[J]. 中华肿瘤防治杂志, 2017, 24(21): 1534-1538.
    唐伟娜, 杨瑞青, 刘斌, 等. 血清CEA和LDH对肺腺癌靶向治疗疗效和预后的评价作用[J]. 临床肺科杂志, 2016, 21(1): 29-32.

    ZHANG Y L, WANG R, LI Y, et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas[J]. J Thorac Oncol, 2015, 10(10): 1444-1450.

    SHOLL L M. Biomarkers in lung adenocarcinoma: a decade of progress[J]. Arch Pathol Lab Med, 2015, 139(4): 469-480.

    SON S M, HAN H S, AN J Y, et al. Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1[J]. Pathology, 2015, 47(2): 123-129.
    赵静, 武二伟, 邢爱民, 等. 119例局部晚期非小细胞肺癌放化疗后预后分析[J]. 临床肺科杂志, 2017, 22(8): 1481-1485.
    卢畅, 申淑景, 毛玉焕, 等. CEA, CYFRA21-1, NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性[J]. 肿瘤防治研究, 2017, 44(7): 485-488.
    陈从华, 明炜, 龚顺松, 等. CEA、NSE及CYFRA21-1对老年非小细胞肺癌患者手术预后判断的价值[J]. 河北医药, 2017, 39(5): 675-677

    , 682.
    马美丽, 韩宝惠. 晚期肺腺癌血浆与组织表皮生长因子受体基因突变检测及预后分析[J]. 世界临床药物, 2017, 38(3): 162-168.
    刘剑, 吉浩明, 刘春桂, 等. 血清CEA、LDH对肺腺癌靶向治疗的临床疗效及预后的预测价值[J]. 实用癌症杂志, 2017, 32(2): 178-180.
    王建玲, 杨嘉, 宋玉良. 晚期肺癌患者化疗前后血清LDH水平变化对化疗疗效及预后的预测[J]. 河北医药, 2016, 38(3): 366-368.
    张旭刚, 李维青, 高颖, 等. 肺腺癌组织中TTF-1表达变化及其与EGFR基因突变、患者预后的关系[J]. 山东医药, 2017, 57(31): 44-46.
    沈维敏, 许佳毅, 唐曦. 原发性肺腺癌alpha-B-crystallin、TTF-1、NapsinA表达研究[J]. 临床和实验医学杂志, 2016, 15(18): 1800-1803.
    • 相关文章
    • 施引文献(5)

  • 期刊类型引用(4)

    1. 黄燕华，邢燕飞，茅敏华. 肺腺癌后再发小细胞肺癌2例报告. 实用临床医药杂志. 2023(01): 68-73 . 本站查看
    2. 王桂英. 贝伐珠单抗联合紫杉醇+顺铂化疗方案治疗肺腺癌患者的近远期效果观察. 黑龙江医学. 2023(10): 1178-1181 . 百度学术
    3. 宫慧敏，邱望仁. 精准医学背景下肺腺癌肿瘤标志物的研究进展. 生物医学工程学进展. 2023(04): 338-346 . 百度学术
    4. 庄大洁，李玉婷，宋忠全，李秀凤，吴立平. 血清Sox2、p53、ST2水平变化与肺腺癌化疗预后转归的关系. 分子诊断与治疗杂志. 2022(06): 996-999 . 百度学术

    其他类型引用(1)

    • 资源附件(0)
计量
  • 文章访问数:  517
  • HTML全文浏览量:  140
  • PDF下载量:  23
  • 被引次数: 5
出版历程
  • 收稿日期:  2020-11-11
  • 网络出版日期:  2020-12-29

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献(5)
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭